Challenges and Opportunities for Respiratory Syncytial Virus Vaccines

ISBN-13: 9783662521557 / Angielski / Miękka / 2016 / 409 str.

Larry J. Anderson; Barney S. Graham

Opis

Although respiratory syncytial virus (RSV) has been a high priority for vaccine development for over 50 years now, still no vaccine is available and none has yet demonstrated sufficient promise to move to licensure.

Recenzje

From the reviews:

"I enjoyed the book: as an immunologist who has spent 10 years working on RSV there were a number of novel insights and it was nice to see it all in one place. ... I will be recommending it to PhD students and Postdocs starting out on RSV research ... . also recommend it to people who have been working with RSV for a while to dip in and out of to fill any gaps in the general knowledge." (John Tregoning, Immunology News, May, 2014)

Spis treści

Part I  Virology,  Pathogenesis, and Clinical and Epidemiological Features of Disease

 

Respiratory Syncytial Virus: Virology, Reverse Genetics, and Pathogenesis of Disease

Peter L. Collins, Rachel Fearns, and Barney S. Graham

 

Clinical and Epidemiologic Features of Respiratory Syncytial Virus
Caroline B. Hall, Eric A. F. Simőes, and Larry J. Anderson

 

Influence of Respiratory Syncytial Virus Strain Differences on Pathogenesis and Immunity

José A. Melero and Martin L. Moore

 

Structure and Function of Respiratory Syncytial Virus Surface Glycoproteins

Jason S. McLellan, William C. Ray and Mark E. Peeples

 

Respiratory Syncytial Virus and Reactive Airway Disease

Matthew T. Lotz, Martin L. Moore, and R. Stokes Peebles, Jr.

 

 

Part II  Host Response to Infection and Genetics of Disease

 

Human Genetics and Respiratory Syncytial Virus Disease: Current Findings and Future Approaches

Eun Hwa Choi, Hoan Jong Lee, and Stephen J. Chanock

 

Innate Immune Responses to Respiratory Syncytial Virus Infection

Sumanta Mukherjee and Nicholas W. Lukacs

 

The Adaptive Immune Response to Respiratory Syncytial Virus

Steven. M. Varga and Thomas J. Braciale

 

Respiratory Syncytial Virus Mechanisms to Interfere with Type 1 Interferons

Sailen Barik

 

Host Gene Expression and Respiratory Syncytial Virus Infection

Ralph A. Tripp, Asuncion Mejias, and Octavio Ramilo

 

Consequences of Immature and Senescent Immune Responses for Infection with Respiratory Syncytial Virus

Allison M.W. Malloy, Ann R. Falsey, and Tracy J. Ruckwardt

 

Part III  Vaccine Platforms and Treatment Options

 

Respiratory Syncytial Virus Disease:  Prevention and Treatment

Helen Y.  Chu and Janet A. Englund

 

Live-Attenuated Respiratory Syncytial Virus Vaccines

Ruth A. Karron, Ursula J. Buchholz, and Peter L. Collins

 

Subunit and Virus-Like Particle Vaccine Approaches for Respiratory Syncytial Virus

Trudy G. Morrison and Edward E. Walsh

 

Gene-Based Vaccine Approaches for Respiratory Syncytial Virus

Rebecca J. Loomis and Philip R. Johnson

Part IV  Animal and Tissue Culture Models of Infection

Bovine Model of Respiratory Syncytial Virus Infection

Geraldine Taylor

 

The Cotton Rat S. hispidus Model of Respiratory Syncytial Virus Infection

Marina S. Boukhvalova and Jorge C.G. Blanco

 

The Mouse Model of Respiratory Syncytial Virus Disease

Peter J. Openshaw

 

Human Airway Epithelial Cell Cultures for Modeling Respiratory Syncytial Virus Infection

Raymond J. Pickles

 

Part V  Conclusions

 

Challenges and Opportunities for Respiratory Syncytial Virus Vaccines

Barney S. Graham and Larry J. Anderson

 

Blurb

Although respiratory syncytial virus (RSV) has been a high priority for vaccine development for over 50 years now, still no vaccine is available and none has yet demonstrated sufficient promise to move to licensure. The success of RSV immune prophylaxis and the availability of ever more powerful tools to study the immune response and pathogenesis of disease, combined with the ability to construct a wide variety of vaccines using different vaccine platforms, give us grounds to believe that an RSV vaccine is within reach. This book brings together in one source what is currently known about the virus: its clinical and epidemiologic features; the host response and pathogenesis of the disease; vaccines, vaccine platforms, and treatment; and animal and tissue culture models of RSV infection. It is designed to organize the critical information relevant to RSV vaccine development, facilitate the assimilation of data, and speed progress toward producing a safe and effective vaccine.